atorvastatin has been researched along with Kidney Failure, Chronic in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 35 (57.38) | 29.6817 |
| 2010's | 25 (40.98) | 24.3611 |
| 2020's | 1 (1.64) | 2.80 |
| Authors | Studies |
|---|---|
| Ayman, EM; Elsayed, MM | 1 |
| Czitrom, D; Ennezat, PV; Le Jemtel, TH; Malergue, MC; Maréchaux, S; Tricot, O; Vincentelli, A | 1 |
| Gonzalo-Martinez, JF; Herrero-San Martin, A; Ostos-Moliz, F; Sanchez-Tejerina San Jose, D; Toldos-Gonzalez, O | 1 |
| Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T | 1 |
| Drechsler, C; Genser, B; Hengstschläger, M; Kaltenecker, CC; Kopecky, C; Krane, V; März, W; Säemann, MD; Wanner, C; Weichhart, T | 1 |
| Berg, AH; Drechsler, C; Hod, T; Kalim, S; Karumanchi, SA; Suntharalingam, P; Thadhani, RI; Wanner, C; Wenger, JB | 1 |
| Bašić-Jukić, N; Ivandić, E | 1 |
| Baumgartner, I; Drechsler, C; Fauler, G; Genser, B; Grammer, TB; Krane, V; März, W; Ritz, E; Scharnagl, H; Silbernagel, G; Wanner, C | 1 |
| Raj, DS; Ramezani, A; Velasquez, MT | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Bai, X; Cai, C; Chen, T; Hou, X; Hu, L; Tian, J; Wu, K | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Bittner, VA; Breazna, A; Carmena, R; Deedwania, PC; Dobson, S; Kastelein, JP; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, AL | 1 |
| Chiang, CK; Hsu, SP; Huang, JW; Hung, KY; Pai, MF; Peng, YS; Wu, KD; Yang, SY | 1 |
| Davidson, MH; Fayyad, RS; Koren, MJ; Reed, DP; Wilson, DJ; Zuckerman, A | 1 |
| Deedwania, P; Singh, V | 1 |
| Boroumand, MA; Djalali, M; Eshragian, MR; Khatami, MR; Shojaei, MH; Siassi, F | 1 |
| Jin, YZ; Min, R; Wang, Q; Zhang, XY; Zhou, X | 1 |
| Ball, MJ; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK; Sharman, JE | 1 |
| Celermajer, DS; Harmer, JA; Kainer, G; Mackie, FE; Rosenberg, AR | 1 |
| Agroyannis, I; Kakavas, I; Papadakis, IT; Petras, D; Stamatelou, K; Stavroulopoulos, A; Stefanadis, C; Vyssoulis, G | 1 |
| Faergeman, O; Fayyad, R; Holdaas, H; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Knap, N; Larczynski, W; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Wozniak, M | 1 |
| Chan, KE; Hakim, RM; Lazarus, JM; Thadhani, R | 1 |
| Tuttle, KR | 1 |
| Ball, MJ; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK | 2 |
| Charlton-Menys, V; Cruickshank, JK; Davies, RR; Dean, J; Durrington, PN; France, M; Gibson, JM; Gittins, M; Jinadev, P; Kalra, PA; Moorhouse, A; Prais, HR; Roberts, C; Rutter, MK; Wiles, PG | 1 |
| Bruggisser, M; Franz, CC; Krähenbühl, S; Rätz Bravo, AE | 1 |
| Allolio, B; Blouin, K; Drechsler, C; Fenske, W; Krane, V; Lilienthal, J; Wanner, C | 1 |
| Ball, MJ; Cardinal, JW; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK | 1 |
| Aref, A; Ehsanpour, A; Ghorbani, A; Shahbazian, H | 1 |
| Blankestijn, PJ; Joles, JA; Oey, PL; Siddiqi, L | 1 |
| Grassi, G; Seravalle, G; Zoccali, C | 1 |
| Cianciaruso, B; Pisani, A; Sabbatini, M; Somma, G; Torraca, S | 1 |
| Dratwa, M; Lameire, NH; Lins, RL; Matthys, KE; Peeters, PC; Stolear, JC; Verpooten, GA | 1 |
| García-Idoate, G; Mora, C; Muros, M; Navarro, JF | 1 |
| Fathi, R; Haluska, B; Isbel, N; Johnson, D; Marwick, TH; Short, L | 1 |
| Athyros, VG; Bouloukos, VI; Elisaf, M; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN | 1 |
| Adachi, M; Gushiken, N; Hirano, T; Hyodo, T; Ikejiri, A; Murayama, S; Taira, T; Yoshino, G | 1 |
| Billiouw, JM; Carpentier, YA; Dratwa, M; Ducobu, J; Dupont, P; Lameire, NH; Lins, RL; Maes, B; Matthys, KE; Peeters, PC; Stolear, JC; Tielemans, C; Verpooten, GA | 1 |
| Bilo, HJ; Diepeveen, SH; Dikkeschei, LD; Kolsters, G; Offerman, JJ; Stalenhoef, AF; Van Der Palen, J; Van Tits, LJ; Verhoeven, GW | 1 |
| Chin, H; Denu-Ciocca, CJ; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS; Pieper, JA | 1 |
| Lavoie, S; Lipson, J; Zimmerman, D | 1 |
| Davidson, M | 1 |
| Brännström, M; Bucht, B; Crougneau, V; Dimeny, E; Ekspong, A; Granroth, B; Gröntoft, KC; Hadimeri, H; Holmberg, B; Ingman, B; Isaksson, B; Johansson, G; Lindberger, K; Lundberg, L; Mikaelsson, L; Olausson, E; Persson, B; Stegmayr, BG; Welin, D; Wikdahl, AM | 1 |
| Ayalon, R; Chernichovski, T; Chernin, G; Levo, Y; Litvak, A; Reshef, R; Schwartz, D; Schwartz, IF; Weinstein, T | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Krane, V; Wanner, C | 1 |
| Healy, H; Morgan, C; Saltissi, D; Westhuyzen, J | 1 |
| Bajo, MA; del Peso, G; Díez, JJ; Estrada, PN; Fernández-Reyes, MJ; Grande, C; Iglesias, P; Sánchez Hernández, R; Selgas, R | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC; van der Steeg, WA | 1 |
| Chan, D; Dogra, G; Irish, A; Watts, G | 1 |
| Budoff, MJ; Gao, YL; Kessler, P; Mao, SS; Moustafa, M; Qunibi, W | 1 |
| Brännström, M; Bucht, S; Crougneau, V; Dimeny, E; Ekspong, A; Eriksson, M; Granroth, B; Gröntoft, KC; Hadimeri, H; Holmberg, B; Ingman, B; Isaksson, B; Johansson, G; Lindberger, K; Lundberg, L; Mikaelsson, L; Olausson, E; Persson, B; Stegmayr, BG; Stenlund, H; Wikdahl, AM | 1 |
| De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C | 1 |
| Bybee, KA; Lee, JH; O'Keefe, JH | 1 |
| Bittner, V; Breazna, A; Deedwania, P; Dobson, S; Kastelein, JJ; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, A | 1 |
| Jaimes, EA; Raij, L; Schuman, IH; Zhou, MS | 1 |
| Böhmig, G; Demetriou, D; Hörl, WH; Schmaldienst, S; Shabpar, A; Watschinger, B | 1 |
| Brophy, DF; Gehr, TW; Holdford, DA; Kennedy, DT; Wallace, JF | 1 |
6 review(s) available for atorvastatin and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Benefit of elective percutaneous coronary intervention for stable coronary artery disease].
Topics: Age Factors; Angina Pectoris; Atorvastatin; Coronary Artery Disease; Diabetic Angiopathies; Elective Surgical Procedures; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Meta-Analysis as Topic; Percutaneous Coronary Intervention; Placebo Effect; Randomized Controlled Trials as Topic; Reoperation; Stents; Surgical Procedures, Operative; Treatment Outcome | 2019 |
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
Topics: Acute Kidney Injury; Atorvastatin; Cardiovascular Diseases; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Risk; Rosuvastatin Calcium; Simvastatin | 2015 |
Reducing morbidity and mortality in high risk patients with statins.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Kidney Failure, Chronic; Metabolic Diseases; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2009 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke | 2008 |
33 trial(s) available for atorvastatin and Kidney Failure, Chronic
| Article | Year |
|---|---|
Atorvastatin can delay arterial stiffness progression in hemodialysis patients.
Topics: Atorvastatin; Blood Pressure; Humans; Kidney Failure, Chronic; Pulse Wave Analysis; Renal Dialysis; Vascular Stiffness | 2022 |
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult | 2014 |
Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Germany; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins, HDL; Male; Middle Aged; Proportional Hazards Models; Pulmonary Surfactant-Associated Protein B; Pyrroles; Renal Dialysis; Risk Factors; Serum Amyloid A Protein; Time Factors; Treatment Outcome | 2015 |
Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Cause of Death; Cholesterol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Renal Dialysis; Risk Factors; Serum Albumin; Survival Rate; Troponin T; Uremia | 2015 |
Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholestanol; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis | 2015 |
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk; Treatment Outcome; United States | 2008 |
Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
Topics: Aged; Anemia; Atorvastatin; Drug Synergism; Erythropoietin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Recombinant Proteins; Renal Dialysis; Tumor Necrosis Factor-alpha | 2009 |
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Follow-Up Studies; Glomerular Filtration Rate; Health Maintenance Organizations; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2009 |
[Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography].
Topics: Aged; Atorvastatin; Contrast Media; Coronary Angiography; Female; Heptanoic Acids; Humans; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles | 2009 |
Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial.
Topics: Adult; Aged; Arteries; Atorvastatin; Blood Pressure; Creatinine; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Pyrroles; Regression Analysis | 2010 |
HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study.
Topics: Adolescent; Atorvastatin; Blood Pressure; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome | 2010 |
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Heart Arrest; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; Regression Analysis; Simvastatin | 2010 |
Atorvastatin attenuates oxidative stress in patients with chronic kidney disease.
Topics: Adult; Atorvastatin; Dinoprost; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoprostanes; Kidney Failure, Chronic; Male; Oxidative Stress; Placebos; Pyrroles | 2010 |
Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2010 |
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
Topics: Albuminuria; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome; United Kingdom | 2011 |
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Biomarkers; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glycopeptides; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Predictive Value of Tests; Pyrroles; Regression Analysis; Risk Factors; Stroke; Treatment Outcome | 2011 |
Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial.
Topics: Acute-Phase Proteins; Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cystatin C; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipocalin-2; Lipocalins; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins; Pyrroles; Young Adult | 2012 |
Alteration of panel-reactive antibodies following treatment with either atorvastatin or low-dose mycophenolate mofetil in sensitized hemodialysis patients.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Failure, Chronic; Male; Mycophenolic Acid; Pyrroles; Renal Dialysis | 2011 |
Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Tolerance; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis | 2003 |
The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Brachial Artery; Carotid Artery, Common; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tunica Intima; Tunica Media; Ultrasonography | 2004 |
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, HDL; Coronary Disease; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles | 2004 |
Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study.
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis; Time Factors; Treatment Outcome | 2004 |
Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
Topics: Adult; alpha-Tocopherol; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Peritoneal Dialysis; Pyrroles; Renal Dialysis; Statistics, Nonparametric; Triglycerides | 2005 |
Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Chronic Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Particle Size; Phenotype; Pilot Projects; Pyrroles; Renal Dialysis; Risk Factors; Triglycerides | 2005 |
Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Prospective Studies; Pyrroles; Severity of Illness Index; Treatment Outcome; Triglycerides | 2005 |
Lessons learnt from the 4D trial.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Placebos; Pyrroles; Renal Dialysis | 2006 |
Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Pyrroles; Renal Dialysis; Triglycerides | 2006 |
A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
Topics: Adult; Aged; Atorvastatin; Brachial Artery; Double-Blind Method; Elasticity; Endothelium, Vascular; Female; Gemfibrozil; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Treatment Outcome | 2007 |
The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study.
Topics: Acetates; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Reproducibility of Results; Sevelamer; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Myocardial Infarction; Prospective Studies; Pyrroles | 2005 |
The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Probability; Pyrroles; Reference Values; Severity of Illness Index; Treatment Outcome | 2008 |
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Pyrroles; Risk; Triglycerides | 2008 |
Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Cyclosporine; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Liver Function Tests; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2000 |
22 other study(ies) available for atorvastatin and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Toxic myopathy associated with concomitant treatment with atorvastatin and colchicine].
Topics: Aged; Arthritis, Gouty; Atorvastatin; Biopsy; Colchicine; Diabetes Mellitus, Type 2; Drug Synergism; Dyslipidemias; Electromyography; Humans; Kidney Failure, Chronic; Male; Muscle, Skeletal; Muscular Diseases; Quadriplegia | 2019 |
[Liver damage caused by atorvastatin and cyclosporine in patients with renal transplant].
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Cyclosporine; Graft Rejection; Graft Survival; Heptanoic Acids; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Liver; Male; Middle Aged; Pyrroles | 2014 |
Urea and protein carbamylation in ESRD: surrogate markers or partners in crime?
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Serum Albumin | 2015 |
Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients.
Topics: Adult; Atorvastatin; C-Reactive Protein; China; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Renal Dialysis; Rosuvastatin Calcium; Treatment Outcome | 2017 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Eating; Female; Folic Acid; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pyrroles; Renal Dialysis; Risk Factors; Vitamin B 6; Vitamin B Complex; Young Adult | 2009 |
Monocyte expression of adhesion molecules during low- and high-flux polysulfone hemodialysis and the effect of atorvastatin administration.
Topics: Adult; Aged; Atorvastatin; CD11b Antigen; CD18 Antigens; Cell Adhesion Molecules; Cross-Over Studies; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; L-Selectin; Male; Middle Aged; Monocytes; Polymers; Pyrroles; Renal Dialysis; Sulfones | 2010 |
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States | 2010 |
Charting new territory by simulated modeling of a clinical trial.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
[Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Coronary Artery Bypass, Off-Pump; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluconazole; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Postoperative Complications; Pyrroles; Rhabdomyolysis | 2011 |
Atorvastatin reduces sympathetic activity in patients with chronic kidney disease.
Topics: Adult; Amides; Arteries; Atorvastatin; Blood Pressure; Case-Control Studies; Female; Fumarates; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Sympathetic Nervous System; Sympatholytics; Time Factors | 2011 |
Sympathoinhibitory effects of statins in chronic kidney disease: are they clinically relevant?
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Pyrroles; Sympathetic Nervous System | 2011 |
Effects of atorvastatin on renal function in patients with chronic renal failure.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Failure, Chronic; Pyrroles | 2002 |
Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Homocysteine; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Renal Dialysis; Risk Factors | 2003 |
Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.
Topics: Alanine Transaminase; Apolipoproteins B; Aspartate Aminotransferases; Atorvastatin; C-Reactive Protein; Cholesterol; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Particle Size; Pyrroles; Renal Dialysis; Triglycerides; Vasculitis | 2004 |
Gabapentin-induced myopathy in 2 patients on short daily hemodialysis.
Topics: Adult; Amines; Anticonvulsants; Atorvastatin; Calcium Channels; Comorbidity; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Glomerulonephritis; Glomerulonephritis, Membranoproliferative; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Neuromuscular Diseases; Peritoneal Dialysis; Physical Exertion; Postoperative Complications; Pyrroles; Recurrence; Renal Dialysis; Restless Legs Syndrome | 2005 |
Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats.
Topics: Animals; Aorta; Arginine; Atorvastatin; Biological Transport; Cationic Amino Acid Transporter 1; Cationic Amino Acid Transporter 2; Creatinine; Gene Expression Regulation; Heptanoic Acids; In Vitro Techniques; Kidney Failure, Chronic; Kidney Glomerulus; Male; Nitric Oxide; Pyrroles; Rats; Rats, Wistar; Uremia | 2006 |
[Hypoadiponectinemia: a cardiovascular risk factor in uremia. A view from the evidence].
Topics: Adiponectin; Animals; Atorvastatin; Cardiovascular Diseases; Coronary Restenosis; Disease Models, Animal; Heptanoic Acids; Humans; Insulin Resistance; Kidney Failure, Chronic; Peritoneal Dialysis; PPAR gamma; Prospective Studies; Pyrroles; Rats; Renal Dialysis; Risk Factors; Thiazolidinediones; Uremia | 2006 |
Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cohort Studies; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles | 2007 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Body Fat Distribution; Body Mass Index; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Kidney Failure, Chronic; Lipid Metabolism; Male; Middle Aged; Nutrition Assessment; Obesity; Prealbumin; Pyrroles; Renal Dialysis; Serum Albumin; Syndrome | 2008 |
Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability.
Topics: Animals; Atorvastatin; Biological Availability; Blood Pressure; Chemokine CCL2; Fibronectins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Failure, Chronic; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Proteinuria; Pyrroles; Rats; Rats, Inbred Dahl; RNA, Messenger; Scavenger Receptors, Class E; Transforming Growth Factor beta | 2008 |
Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia.
Topics: Atorvastatin; Calcium Carbonate; Cost-Benefit Analysis; Decision Support Techniques; Epoxy Compounds; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Lipoproteins, LDL; Phosphates; Polyamines; Polyethylenes; Pyrroles; Sevelamer | 2000 |